Granules India Limited has informed the Exchange about General Updates
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Granules India announced that its API Unit-I facility at Bonthapally (Sangareddy, Hyderabad) completed a US FDA inspection conducted from June 16 to June 20, 2025. The inspection concluded with 1 Form 483 observation, which the company says it will respond to within the required timeframe. The Bonthapally plant is described as one of the world's largest single-site Paracetamol API manufacturing facilities by volume, and also produces Metformin and Guaifenesin APIs. The filing was made under SEBI Listing Regulations (Reg 30) as a general update to the exchanges.
A single 483 observation is generally considered routine and minor for a US FDA-inspected facility, with no indication of an import alert, warning letter, or Official Action Indicated (OAI) status. For shareholders, this is a broadly neutral-to-mildly-positive update, as it confirms continued US regulatory compliance for a key manufacturing site, though the market may watch the company's response closely.